Perivascular Epithelioid Cell Neoplasms are rare tumors. They are made up of special cells that grow around blood vessels. These tumors can occur in different parts of the body. They are usually treated with surgery.
Every report comes from a Lived member, sent anonymously.
Have you tried Sirolimus for Perivascular Epithelioid Cell Tumors?
Perivascular epithelioid cell tumors, usually called PEComas, are a rare family of tumors that grow from an unusual cell type found around small blood vessels. Under the microscope these cells look partly like smooth muscle cells and partly like pigment-producing cells, a combination that is what defines the tumor. PEComas can appear almost anywhere in the body, but the uterus, liver, kidney, digestive tract and soft tissues are among the more common places. Most PEComas are benign, meaning they do not spread, and complete removal is often the end of the problem. A smaller share behave like a cancer (a type of sarcoma): they can grow into nearby tissue, come back after surgery or spread to other organs, most often the lungs. The name is also used as an umbrella. Kidney angiomyolipoma and lymphangioleiomyomatosis (LAM), a rare lung disease, belong to the same family but have their own course and treatment. This page focuses on the PEComa tumors outside those two conditions.
Researchers do not yet know why most PEComas form, and no lifestyle habit or exposure is known to cause them. In many tumors, changes in genes called TSC1 or TSC2 switch on a growth signal inside the cell known as mTOR. That pathway matters because it is also the target of the main drug treatment. A smaller group of tumors has a different change involving a gene called TFE3. In most people these gene changes arise only in the tumor and are not inherited. A minority of PEComas occur in people with tuberous sclerosis complex, a genetic condition caused by TSC1 or TSC2 variants that also causes benign tumors in the brain and other organs. PEComas are diagnosed more often in women, usually in middle age. Some reports describe tumors growing during pregnancy, and estrogen may play a role, but this link is not well understood.
A PEComa is often found by chance on a scan done for another reason. When it does cause symptoms, they depend on where it is: a uterine tumor may cause abnormal bleeding, while a liver or abdominal tumor may cause pain, fullness or nausea. On CT or MRI scans, PEComas tend to look like more common tumors, such as liver cancer, a uterine sarcoma or a fibroid, and blood tests are usually normal. Imaging can raise the possibility but cannot confirm the diagnosis. Confirmation requires tissue, from a biopsy or from the tumor after it has been removed. A pathologist uses special stains that show both muscle markers and pigment-cell markers (such as HMB-45 and Melan-A) on the same tumor cells. Because the tumor is rare, review by a pathologist experienced with sarcomas is often worthwhile. The pathologist also judges how likely the tumor is to behave aggressively. The most widely used approach looks for warning features: a size over 5 centimeters (about 2 inches), growth into surrounding tissue, very abnormal-looking cell nuclei, areas of dead tumor tissue (necrosis), tumor cells inside blood vessels, and rapidly dividing cells. A tumor with two or more of these is generally classified as malignant, one with fewer may be labeled benign or of uncertain potential. These categories guide treatment and follow-up, but they are not perfect predictions, especially for tumors in the liver.
For a PEComa that has not spread, surgery to remove the whole tumor with a rim of normal tissue is the main treatment, and for many people it is the only one needed. The operation depends on the location, from removing part of the liver to a hysterectomy for a uterine tumor. Surgery also gives the pathologist the complete tumor to examine, which is often how the diagnosis and risk category are finally settled. For a small tumor with no worrying features, some specialists consider watching it with repeat scans instead, though how these tumors will behave is hard to predict. When a malignant PEComa cannot be removed or has spread, the main drug treatment is an mTOR inhibitor, a medicine that blocks the growth signal many PEComas depend on. Sirolimus protein-bound particles (Fyarro), given as an intravenous infusion twice in each three-week cycle, is approved by the FDA for adults with advanced malignant PEComa. In the study that led to its approval, the tumors shrank substantially in about 4 of 10 people, and for many of them the benefit lasted more than a year. It does not cure the cancer, and some tumors, including some with TFE3 changes, respond poorly. Other mTOR inhibitors taken by mouth, such as sirolimus and everolimus, have also been used. Mouth sores are very common, and infections and low blood counts can occur, so treatment involves regular blood tests and dose adjustments. Chemotherapy used for other sarcomas shrinks PEComas less often and for a shorter time, so it is usually considered when mTOR inhibitors no longer work. Radiation, or procedures that destroy or cut off the blood supply to tumors in the liver, may help control specific sites. Because so few people have this tumor, care at a sarcoma center and clinical trials are worth asking about.
The outlook depends largely on the tumor's risk category. Many people with a benign PEComa that was completely removed have no further problems. Malignant tumors are more likely to return in the same place or appear in the lungs, liver, bones or abdomen, and this can happen within months or many years after surgery, occasionally even when the original tumor looked low risk. For that reason, follow-up usually means periodic CT or MRI scans for years after treatment, with more frequent scans after a higher-risk tumor. There is no agreed standard schedule, so the plan is set by the treating team. People living with advanced PEComa often take mTOR inhibitor treatment for as long as it keeps the disease under control, with regular scans to check whether it is still working. Because the evidence comes mostly from small studies, doctors cannot give precise survival estimates, and individual courses vary widely.
See a doctor about symptoms that point to a growing mass, such as abnormal vaginal bleeding, a lump that is getting bigger, or abdominal pain or fullness that does not go away. After treatment, tell your care team about a new lump, a persistent cough, new pain or unexplained weight loss rather than waiting for the next scheduled scan. During mTOR inhibitor treatment, contact the care team promptly about fever or other signs of infection, or mouth sores that make it hard to eat or drink. Sudden, severe abdominal pain in someone with a large abdominal PEComa needs emergency care, because a large tumor can occasionally bleed or rupture.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Perivascular Epithelioid Cell Tumors is like, what's helped you, or ask the community a question.